Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia-Reference-Cited by-同舟云学术

Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia

Published:2022-02-24 Issue:1 Volume:98 Page:122-130
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Goshua George¹²^ORCID,Sinha Pranay²³^ORCID,Kunst Natalia⁴^ORCID,Pischel Lauren⁵⁶^ORCID,Lee Alfred Ian¹,Cuker Adam⁷

Affiliation:

1. Section of Hematology Yale University School of Medicine New Haven Connecticut USA

2. Department of Health Policy and Management Harvard T.H. Chan School of Public Health Boston Massachusetts USA

3. Section of Infectious Diseases Boston Medical Center Boston Massachusetts USA

4. Department of Population Medicine Harvard Medical School and Harvard Pilgrim Healthcare Institute Boston Massachusetts USA

5. Section of Infectious Diseases Yale University School of Medicine New Haven Connecticut USA

6. Department of Epidemiology of Microbial Diseases Yale School of Public Health New Haven Connecticut USA

7. Department of Medicine and Department of Pathology & Laboratory Medicine, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26497

Reference40 articles.

1. American Society of Hematology 2019 guidelines for immune thrombocytopenia

2. Immune thrombocytopenia.2019. Accessed July 23 2021.https://rarediseases.org/rare-diseases/immune-thrombocytopenia/

3. The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort

4. Healthcare burden of rare diseases in Hong Kong – adopting ORPHAcodes in ICD-10 based healthcare administrative datasets

5. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey;Biomolecules;2024-04-18

2. Proteomics landscape and machine learning prediction of long‐term response to splenectomy in primary immune thrombocytopenia;British Journal of Haematology;2024-03-21

3. Splenectomy outcomes in immune cytopenias: Treatment outcomes and determinants of response;Journal of Internal Medicine;2023-11-13

4. Napkin math can change the world;Science;2023-11-10

5. Is splenectomy a good strategy for refractory immune thrombocytopenia in adults?;British Journal of Haematology;2023-09-21